REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34.

2. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol 2012;30:195-200.

3. Adesunloye BA, Karzai FH, Dahut WL. Angiogenesis inhibitors in the treatment of prostate cancer. In: Marone G, Granata F, editors. Angiogenesis, Lymphangiogenesis and Clinical Implications. Basel: S. KARGER AG; 2013. pp. 197-215.

4. Varenhorst E, Klaff R, Berglund A, Hedlund PO, Sandblom G; Scandinavian Prostate Cancer Group (SPCG) Trial No. 5. Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases. Cancer Med 2016;5:407-14.

5. Frieling JS, Basanta D, Lynch CC. Current and emerging therapies for bone metastatic castration-resistant prostate cancer. Cancer Control 2015;22:109-20.

6. Desai B, Rogers MJ, Chellaiah MA. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer 2007;6:18.

7. Cooper CR, Chay CH, Pienta KJ. The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 2002;4:191-4.

8. Weber GF, Ashkar S. Molecular mechanisms of tumor dissemination in primary and metastatic brain cancers. Brain Res Bull 2000;53:421-4.

9. Naor D, Vogt Sionov R, Zahalka M, Rochman M, Holzmann B, et al. Organ-specific requirements for cell adhesion molecules during lymphoma cell dissemination. In: Holzmann B, Wagner H, editors. Leukocyte integrins in the immune system and malignant disease. Berlin: Springer Berlin Heidelberg; 1998. pp. 143-66.

10. Sy MS, Guo YJ, Stamenkovic I. Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 1991;174:859-66.

11. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol 1999;52:189-96.

12. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271:509-12.

13. Desai B, Ma T, Chellaiah MA. Invadopodia and matrix degradation, a new property of prostate cancer cells during migration and invasion. J Biol Chem 2008;283:13856-66.

14. Chellaiah MA, Kizer N, Biswas R, Alvarez U, Strauss-Schoenberger J, et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 2003;14:173-89.

15. Desai B, Ma T, Zhu J, Chellaiah MA. Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface. J Cell Biochem 2009;108:272-84.

16. Gupta A, Cao W, Chellaiah MA. Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis. Mol Cancer 2012;11:66.

17. Srinivasan D, Senbanjo L, Majumdar S, Franklin RB, Chellaiah MA. Androgen receptor expression reduces stemness characteristics of prostate cancer cells (PC3) by repression of CD44 and SOX2. J Cell Biochem 2018:2413-28.

18. Murakami D, Okamoto I, Nagano O, Kawano Y, Tomita T, et al. Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44. Oncogene 2003;22:1511-6.

19. Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, et al. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol 2001;155:755-62.

20. Okamoto I, Kawano Y, Tsuiki H, Sasaki J, Nakao M, et al. CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration. Oncogene 1999;18:1435-46.

21. Miletti-González KE, Murphy K, Kumaran MN, Ravindranath AK, Wernyj RP, et al. Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element. J Biol Chem 2012;287:18995-9007.

22. Senbanjo LT, AlJohani H, Majumdar S, Chellaiah MA. Characterization of CD44 intracellular domain interaction with RUNX2 in PC3 human prostate cancer cells. Cell Commun Signal 2019;17:80.

23. van der Deen M, Akech J, Wang T, FitzGerald TJ, Altieri DC, et al. The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells. J Cell Biochem 2010;109:828-37.

24. Zhang X, Wu H, Dobson JR, Browne G, Hong D, et al. Expression of the IL-11 Gene in Metastatic Cells Is Supported by Runx2-Smad and Runx2-cJun Complexes Induced by TGFβ1. J Cell Biochem 2015;116:2098-108.

25. Pratap J, Lian JB, Stein GS. Metastatic bone disease: role of transcription factors and future targets. Bone 2011;48:30-6.

26. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010;29:811-21.

27. Chua CW, Chiu YT, Yuen HF, Chan KW, Man K, et al. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin Cancer Res 2009;15:4322-35.

28. Park JS, Park MK, Oh HJ, Woo YJ, Lim MA, et al. Grape-seed proanthocyanidin extract as suppressors of bone destruction in inflammatory autoimmune arthritis. PLoS One 2012;7:e51377.

29. Neumann C, Garreis F, Paulsen F, Hammer CM, Birke MT, et al. Osteopontin is induced by TGF-β2 and regulates metabolic cell activity in cultured human optic nerve head astrocytes. PLoS One 2014;9:e92762.

30. Chellaiah M, Hruska K. Osteopontin stimulates gelsolin-associated phosphoinositide levels and phosphatidylinositol triphosphate-hydroxyl kinase. Mol Biol Cell 1996;7:743-53.

31. Chellaiah M, Fitzgerald C, Alvarez U, Hruska K. c-Src is required for stimulation of gelsolin-associated phosphatidylinositol 3-kinase. J Biol Chem 1998;273:11908-16.

32. Schneider A, Younis RH, Gutkind JS. Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. Neoplasia 2008;10:1295-302.

33. Cho Y, Lee HW, Kang HG, Kim HY, Kim SJ, et al. Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer. Oncotarget 2015;6:8709-21.

34. Cichy J, Puré E. The liberation of CD44. J Cell Biol 2003;161:839-43.

35. Okamoto I, Tsuiki H, Kenyon LC, Godwin AK, Emlet DR, et al. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol 2002;160:441-7.

36. Liu X, Rose DP. Stimulation of type IV collagenase expression by linoleic acid in a metastatic human breast cancer cell line. Cancer Letters 1994;76:71-7.

37. Masson D, Denis MG, Denis M, Blanchard D, Loirat MJ, et al. Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer. Br J Cancer 1999;80:1995-2000.

38. Gupta A, Cao W, Sadashivaiah K, Chen W, Schneider A, et al. Promising noninvasive cellular phenotype in prostate cancer cells knockdown of matrix metalloproteinase 9. ScientificWorldJournal 2013;2013:493689.

39. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 2006;25:589-600.

40. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, et al. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 2005;25:8581-91.